Literature DB >> 30977182

Intensive chemotherapy is more effective than hypomethylating agents for the treatment of younger patients with myelodysplastic syndrome and elevated bone marrow blasts.

Paolo Strati1, Guillermo Garcia-Manero1, Chong Zhao2, Tapan Kadia1, Gautam Borthakur1, Marina Konopleva1, Naval Daver1, Courtney D DiNardo1, Nicholas J Short1, Musa Yilmaz1, Kiran Naqvi1, Yesid Alvarado1, Sherry A Pierce1, Jorge Cortes1, Carlos Bueso-Ramos2, Hagop Kantarjian1, Farhad Ravandi1.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 30977182      PMCID： PMC6566858          DOI： 10.1002/ajh.25490

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  5 in total

1.  High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens.

Authors:  M Beran; Y Shen; H Kantarjian; S O'Brien; C A Koller; F J Giles; J Cortes; D A Thomas; S Faderl; S Despa; E H Estey
Journal:  Cancer       Date:  2001-10-15       Impact factor: 6.860

2.  Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis.

Authors:  John Koreth; Joseph Pidala; Waleska S Perez; H Joachim Deeg; Guillermo Garcia-Manero; Luca Malcovati; Mario Cazzola; Sophie Park; Raphael Itzykson; Lionel Ades; Pierre Fenaux; Martin Jadersten; Eva Hellstrom-Lindberg; Robert Peter Gale; C L Beach; Stephanie J Lee; Mary M Horowitz; Peter L Greenberg; Martin S Tallman; John F DiPersio; Donald Bunjes; Daniel J Weisdorf; Corey Cutler
Journal:  J Clin Oncol       Date:  2013-06-24       Impact factor: 44.544

3.  Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

Authors:  Pierre Fenaux; Ghulam J Mufti; Eva Hellstrom-Lindberg; Valeria Santini; Carlo Finelli; Aristoteles Giagounidis; Robert Schoch; Norbert Gattermann; Guillermo Sanz; Alan List; Steven D Gore; John F Seymour; John M Bennett; John Byrd; Jay Backstrom; Linda Zimmerman; David McKenzie; Cl Beach; Lewis R Silverman
Journal:  Lancet Oncol       Date:  2009-02-21       Impact factor: 41.316

4.  Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

Authors:  Courtney D DiNardo; Guillermo Garcia-Manero; Sherry Pierce; Aziz Nazha; Carlos Bueso-Ramos; Elias Jabbour; Farhad Ravandi; Jorge Cortes; Hagop Kantarjian
Journal:  Am J Hematol       Date:  2016-02       Impact factor: 10.047

5.  TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.

Authors:  John S Welch; Allegra A Petti; Christopher A Miller; Catrina C Fronick; Michelle O'Laughlin; Robert S Fulton; Richard K Wilson; Jack D Baty; Eric J Duncavage; Bevan Tandon; Yi-Shan Lee; Lukas D Wartman; Geoffrey L Uy; Armin Ghobadi; Michael H Tomasson; Iskra Pusic; Rizwan Romee; Todd A Fehniger; Keith E Stockerl-Goldstein; Ravi Vij; Stephen T Oh; Camille N Abboud; Amanda F Cashen; Mark A Schroeder; Meagan A Jacoby; Sharon E Heath; Kierstin Luber; Megan R Janke; Andrew Hantel; Niloufer Khan; Madina J Sukhanova; Randall W Knoebel; Wendy Stock; Timothy A Graubert; Matthew J Walter; Peter Westervelt; Daniel C Link; John F DiPersio; Timothy J Ley
Journal:  N Engl J Med       Date:  2016-11-24       Impact factor: 91.245
  5 in total
  1 in total

Review 1.  Following in the footsteps of acute myeloid leukemia: are we witnessing the start of a therapeutic revolution for higher-risk myelodysplastic syndromes?

Authors:  Jan Philipp Bewersdorf; Amer M Zeidan
Journal:  Leuk Lymphoma       Date:  2020-05-18
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.